Five-Year JULIET Trial Data Confirms Tisagenlecleucel as Curative CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma
核心洞察
Five-year follow-up data from the JULIET trial demonstrates tisagenlecleucel (tisa-cel (搜索)) maintains a 53% overall response rate and 39.1% complete response rate in relapsed/refractory large B-cell lymphoma (搜索) patients.
The CAR-T therapy shows durable efficacy with 84.6% of complete responders remaining in remission at 60 months and median overall survival of 76.5 months among responders.
Long-term safety analysis reveals no new safety signals after five years, with no secondary T-cell malignancies reported and manageable late-onset adverse events in 40% of evaluable patients.
Five-year follow-up data from the pivotal JULIET trial confirms tisagenlecleucel (tisa-cel (搜索); Kymriah) as a transformative and potentially curative therapy for patients with relapsed/refractory large B-cell lymphoma (搜索) (R/R LBCL), demonstrating sustained efficacy and a favorable long-term safety profile without new safety signals.
The global phase 2 JULIET trial (NCT02445248) enrolled 115 patients with R/R LBCL and evaluated the chimeric antigen receptor (CAR) T-cell therapy over an extended follow-up period. The updated analysis, published in the Journal of Clinical Oncology, shows an overall response rate of 53% (n = 61/115) and a best overall response of complete response (CR) in 39.1% of patients (n = 45/115).
Durable Response Conversions and Long-Term Outcomes
A notable finding was the conversion of partial responses to complete responses in 19 patients, with 78.9% of these conversions occurring within 6 months of infusion. The latest conversion occurred between 24 and 36 months post-infusion, demonstrating the therapy's potential for delayed but durable responses. Among 30 patients still in follow-up at 60 months, 26 had achieved CR as their best overall response, with 22 (84.6%) remaining in complete remission at the 60-month mark.
The median duration of response was not evaluable in the total patient population and was not reached among responders. The 60-month relapse-free probability was 60.5% (95% CI, 46.3%-72%) in the responders group, while the 57-month event-free probability among patients with complete response was 75.7% (95% CI, 58.3%-86.6%).
Survival Benefits Sustained Over Time
Overall survival data revealed significant differences between responders and the total population. The median overall survival was 11.1 months (95% CI, 6.6-23.9) for all patients but reached 76.5 months (95% CI, 37.8-NE) among responders. The 60-month overall survival probability was 31.7% (95% CI, 23.1%-40.6%) versus 55.8% (95% CI, 41.9%-67.7%) between the total population and responders, respectively.
The estimated 60-month progression-free survival probability was 28% (95% CI, 19.5%-37.8%) for all patients. The median disease-specific survival was 21.2 months (95% CI, 10.1-NE) for the total population versus not evaluable for responders.
Favorable Long-Term Safety Profile
The five-year safety analysis confirmed a manageable long-term safety profile with no new or unexpected late safety issues. Among 35 patients evaluable for safety more than three years after infusion, 14 (40%) experienced late-onset adverse events, with 22.9% having any-grade infections and 22.9% experiencing grade 3/4 adverse events.
A total of 76 deaths were reported, with disease progression being the most common cause (78%). The majority of deaths (92%) occurred within 36 months of infusion. Only four deaths occurred more than three years post-infusion and were not related to disease relapse, caused by myelodysplastic syndrome (搜索) (n = 2), bacterial sepsis (搜索) (n = 1), and respiratory failure (搜索) (n = 1).
Secondary malignancies were reported in 15 events across 13 patients (11.3%), but importantly, no secondary T-cell malignancies were observed. No replication-competent lentivirus was detected at any point, and there was no evidence of CAR-transgene or RCL-mediated cell transformation.
Biomarker Insights for Patient Selection
The study identified several baseline characteristics and biomarkers significantly associated with clinical response and long-term survival. Patients more likely to achieve responses had relapsed/refractory disease, one (versus two or more) bridging regimens, lactate dehydrogenase (LDH) levels at or below the upper limit of normal, and C-reactive protein (CRP) levels below 15 mg/L.
Myc (搜索) status emerged as a critical prognostic factor. Patients with Myc-negative tumors demonstrated significantly longer progression-free survival and overall survival compared to those with Myc-positive tumors. The median PFS was 6.2 months for Myc-negative versus 2.5 months for Myc-positive patients, while median OS was 21 months versus 7.8 months, respectively.
Tumor immune microenvironment characteristics also proved predictive. Higher infiltration of T cells (CD3 (搜索)+ >3%) in the tumor was associated with longer PFS and OS, while higher levels of exhausted T cells (LAG3 (搜索)+CD3+ >20%) were linked to poorer outcomes.
CAR-T Cell Persistence and Durability
Long-term persistence of CAR-T cells was observed in both responders and non-responders, indicating the durability of the cellular product after infusion. The tisa-cel (搜索) transgene was detected in peripheral blood for up to 1,830 days in responders and up to 1,480 days in non-responders, demonstrating sustained cellular activity well beyond the initial treatment period.
Establishing CAR-T as Standard of Care
"These findings continue to demonstrate the long-term survival benefit of tisagenlecleucel without new safety signals in [R/R] LBCL," concluded study authors led by Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University Knight Cancer Institute (搜索). "The results support the role of tisagenlecleucel as a transformative therapy for [R/R] LBCL and provide critical evidence for long-term risk-benefit assessment."
The researchers emphasized that "the JULIET trial has been foundational in establishing CAR-T-cell therapy as a curative standard-of-care option for patients with [R/R] LBCL in the third-line setting and provided valuable safety and scientific insights and knowledge that advanced the field, expanding the potential for CAR-T cell therapy to multiple new applications."
Patients completing the initial five-year JULIET follow-up period can enroll in the PAVO study (NCT02445222) for an additional 10 years of follow-up, ensuring continued monitoring of this landmark therapy's long-term effects.